Type 2 diabetes impairs venous, but not arterial smooth muscle cell function: Possible role of differential RhoA activity

Cardiovascular Revascularization Medicine

Volumn 15, Issue 3, 2014, Pages 141-148

  Riches, Kirsten ^a,b   Warburton, Philip ^a   O'Regan, David J ^b,c   Turner, Neil A ^a,b   Porter, Karen E ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Cell phenotype; Internal mammary artery; RhoA; Saphenous vein; Smooth muscle cell; Type 2 diabetes

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; F ACTIN; MESSENGER RNA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; VINCULIN; RHOA PROTEIN, HUMAN;

ADULT; AGED; ARTERIAL SMOOTH MUSCLE CELL; ARTERY MUSCLE; ARTICLE; CELL COUNTING; CELL FUNCTION; CELL PROLIFERATION; CELL SPREADING; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; DIABETIC PATIENT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INTERNAL MAMMARY ARTERY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAPHENOUS VEIN; SAPHENOUS VEIN GRAFT; SMOOTH MUSCLE FIBER; VENOUS SMOOTH MUSCLE CELL; WESTERN BLOTTING; CASE CONTROL STUDY; CELL CULTURE; CELL SHAPE; COMPARATIVE STUDY; COMPLICATION; DIABETIC ANGIOPATHIES; DOWN REGULATION; ENZYMOLOGY; MAMMARY ARTERY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; TIME; VASCULAR SMOOTH MUSCLE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELL SHAPE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOWN-REGULATION; FEMALE; HUMANS; MALE; MAMMARY ARTERIES; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; RHOA GTP-BINDING PROTEIN; SAPHENOUS VEIN; TIME FACTORS;

EID: 84899637150     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2014.02.005     Document Type: Article

References (36)

1. Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001, 44(Suppl 2):S14-S21.
2. Hu F.B., Stampfer M.J., Haffner S.M., Solomon C.G., Willett W.C., Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25(7):1129-1134.
3. Motwani J.G., Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998, 97(9):916-931.
4. Kubal C., Srinivasan A.K., Grayson A.D., Fabri B.M., Chalmers J.A. Effect of risk-adjusted diabetes on mortality and morbidity after coronary artery bypass surgery. Ann Thorac Surg 2005, 79(5):1570-1576.
5. Hemo E., Mohr R., Uretzky G., Katz G., Popovits N., Pevni D., et al. Long-term outcomes of patients with diabetes receiving bilateral internal thoracic artery grafts. J Thorac Cardiovasc Surg 2013, 146(3):586-592.
6. Canham P.B., Finlay H.M., Boughner D.R. Contrasting structure of the saphenous vein and internal mammary artery used as coronary bypass vessels. Cardiovasc Res 1997, 34(3):557-567.
7. Lorusso R., Pentiricci S., Raddino R., Scarabelli T.M., Zambelli C., Villanacci V., et al. Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits. Diabetes 2003, 52(11):2814-2820.
8. Owens C.D. Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications. J Vasc Surg 2010, 51(3):736-746.
9. Kavurma M.M., Khachigian L.M. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 2003, 89(2):289-300.
10. van Nieuw Amerongen G.P., van Hinsbergh V.W. Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol 2001, 21(3):300-311.
11. Loirand G., Rolli-Derkinderen M., Pacaud P. RhoA and resistance artery remodeling. Am J Physiol Heart Circ Physiol 2005, 288(3):H1051-H1056.
12. Peng F., Wu D., Gao B., Ingram A.J., Zhang B., Chorneyko K., et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008, 57(6):1683-1692.
13. Zhou H., Li Y.J., Wang M., Zhang L.H., Guo B.Y., Zhao Z.S., et al. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol Sin 2011, 32(8):999-1008.
14. Madi H.A., Riches K., Warburton P., O'Regan D.J., Turner N.A., Porter K.E. Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients. Am J Physiol Cell Physiol 2009, 297(5):C1307-C1317.
15. Porter K.E., Naik J., Turner N.A., Dickinson T., Thompson M.M., London N.J. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002, 36(1):150-157.
16. Turner N.A., Mughal R.S., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res 2007, 76(1):81-90.
17. Turner N.A., Ball S.G., Balmforth A.J. The mechanism of angiotensin II-induced extracellular signal-regulated kinase-1/2 activation is independent of angiotensin AT(1A) receptor internalisation. Cell Signal 2001, 13(4):269-277.
18. Turner N.A., Ho S., Warburton P., O'Regan D.J., Porter K.E. Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. J Vasc Surg 2007, 45(5):1022-1028.
19. Wong A.P., Nili N., Jackson Z.S., Qiang B., Leong-Poi H., Jaffe R., et al. Expansive remodeling in venous bypass grafts: novel implications for vein graft disease. Atherosclerosis 2008, 196(2):580-589.
20. Worth N.F., Rolfe B.E., Song J., Campbell G.R. Vascular smooth muscle cell phenotypic modulation in culture is associated with reorganisation of contractile and cytoskeletal proteins. Cell Motil Cytoskeleton 2001, 49(3):130-145.
21. Weiss S., Frischknecht K., Greutert H., Payeli S., Steffel J., Luscher T.F., et al. Different Migration Of Vascular Smooth Muscle Cells From Human Coronary Artery Bypass Vessels. Role Of Rho/ROCK Pathway. J Vasc Res 2007, 44(2):149-156.
22. Takeda N., Kondo M., Ito S., Ito Y., Shimokata K., Kume H. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 2006, 35(6):722-729.
23. Ding R., Hu D.Y., Xia K., Yang X.C. Increased RhoA/ROK mRNA expression and function in diabetic vein grafts compared with nondiabetic vein grafts and diabetic arterial grafts. Thorac Cardiovasc Surg 2010, 58(3):148-153.
24. Kun X., Lefeng W., Rongjing D., Xincun Y. RhoA/ROK pathway related to the mechanism of higher susceptibility to spasm in RA than in IMA. J Card Surg 2009, 24(6):766-771.
25. Matsuo Y., Kuwabara M., Tanaka-Totoribe N., Kanai T., Nakamura E., Gamoh S., et al. The defective protein level of myosin light chain phosphatase (MLCP) in the isolated saphenous vein, as a vascular conduit in coronary artery bypass grafting (CABG), harvested from patients with diabetes mellitus (DM). Biochem Biophys Res Commun 2011, 412(2):323-327.
26. Tang J., Fitzgerald S.M., Boughtman B.N., Cole S.W., Brands M.W., Zhang J.H. Decreased RhoA expression in myocardium of diabetic rats. Can J Physiol Pharmacol 2005, 83(8-9):775-783.
27. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233.
28. Chiba Y., Tanabe M., Goto K., Sakai H., Misawa M. Down-regulation of miR-133a contributes to up-regulation of Rhoa in bronchial smooth muscle cells. Am J Respir Crit Care Med 2009, 180(8):713-719.
29. Granjon A., Gustin M.P., Rieusset J., Lefai E., Meugnier E., Guller I., et al. The microRNA signature in response to insulin reveals its implication in the transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding protein-1c/myocyte enhancer factor 2C pathway. Diabetes 2009, 58(11):2555-2564.
30. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84(3):767-801.
31. Porter K.E., Riches K. The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes?. Clin Sci (Lond) 2013, 125(4):167-182.
32. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
33. Brown A., Reynolds L.R., Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010, 7(7):369-375.
34. Skyler J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.A., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009, 119(2):351-357.
35. Cooper M.E. Metabolic memory: implications for diabetic vascular complications. Pediatr Diabetes 2009, 10(5):343-346.
36. Villeneuve L.M., Reddy M.A., Natarajan R. Epigenetics: deciphering its role in diabetes and its chronic complications. Clin Exp Pharmacol Physiol 2011, 38(7):451-459.